CITIUS ONCOLOGY INC (CTOR) Fundamental Analysis & Valuation

NASDAQ:CTOR • US17331Y1091

Current stock price

0.8801 USD
+0.02 (+2.34%)
Last:

This CTOR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CTOR Profitability Analysis

1.1 Basic Checks

  • CTOR had negative earnings in the past year.
  • CTOR had a negative operating cash flow in the past year.
CTOR Yearly Net Income VS EBIT VS OCF VS FCFCTOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 2025 -5M -10M -15M -20M

1.2 Ratios

  • The Return On Assets of CTOR (-21.49%) is better than 74.17% of its industry peers.
  • CTOR's Return On Equity of -40.46% is fine compared to the rest of the industry. CTOR outperforms 67.77% of its industry peers.
Industry RankSector Rank
ROA -21.49%
ROE -40.46%
ROIC N/A
ROA(3y)-24.09%
ROA(5y)N/A
ROE(3y)-34.59%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTOR Yearly ROA, ROE, ROICCTOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 2025 -10 -20 -30 -40 -50

1.3 Margins

  • CTOR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTOR Yearly Profit, Operating, Gross MarginsCTOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. CTOR Health Analysis

2.1 Basic Checks

  • CTOR has more shares outstanding than it did 1 year ago.
  • CTOR has a worse debt/assets ratio than last year.
CTOR Yearly Shares OutstandingCTOR Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2025 20M 40M 60M 80M
CTOR Yearly Total Debt VS Total AssetsCTOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -0.72, we must say that CTOR is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of CTOR (-0.72) is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.07 indicates that CTOR is not too dependend on debt financing.
  • CTOR has a Debt to Equity ratio of 0.07. This is in the lower half of the industry: CTOR underperforms 60.97% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -0.72
ROIC/WACCN/A
WACCN/A
CTOR Yearly LT Debt VS Equity VS FCFCTOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2025 0 20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 0.83 indicates that CTOR may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.83, CTOR is doing worse than 88.74% of the companies in the same industry.
  • A Quick Ratio of 0.32 indicates that CTOR may have some problems paying its short term obligations.
  • CTOR has a worse Quick ratio (0.32) than 93.79% of its industry peers.
Industry RankSector Rank
Current Ratio 0.83
Quick Ratio 0.32
CTOR Yearly Current Assets VS Current LiabilitesCTOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. CTOR Growth Analysis

3.1 Past

  • CTOR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.31%, which is quite impressive.
EPS 1Y (TTM)30.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, CTOR will show a very strong growth in Earnings Per Share. The EPS will grow by 61.98% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y43%
EPS Next 2Y78.04%
EPS Next 3Y61.98%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CTOR Yearly Revenue VS EstimatesCTOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 50M 100M 150M
CTOR Yearly EPS VS EstimatesCTOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

Find the best growth stocksShow best growing peers

4

4. CTOR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CTOR. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 2.21, the valuation of CTOR can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, CTOR is valued cheaply inside the industry as 99.42% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of CTOR to the average of the S&P500 Index (21.68), we can say CTOR is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 2.21
CTOR Price Earnings VS Forward Price EarningsCTOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTOR Per share dataCTOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6

4.3 Compensation for Growth

  • CTOR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as CTOR's earnings are expected to grow with 61.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y78.04%
EPS Next 3Y61.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CTOR Dividend Analysis

5.1 Amount

  • No dividends for CTOR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CTOR Fundamentals: All Metrics, Ratios and Statistics

CITIUS ONCOLOGY INC

NASDAQ:CTOR (4/30/2026, 2:04:37 PM)

0.8801

+0.02 (+2.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength54.66
Industry Growth13.04
Earnings (Last)02-13
Earnings (Next)05-20
Inst Owners7.67%
Inst Owner Change0.27%
Ins Owners0.96%
Ins Owner Change0%
Market Cap77.70M
Revenue(TTM)3.94M
Net Income(TTM)-23.64M
Analysts82.86
Price Target6.12 (595.38%)
Short Float %4.82%
Short Ratio3.44
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-73.53%
Min EPS beat(2)-198.04%
Max EPS beat(2)50.98%
EPS beat(4)2
Avg EPS beat(4)-29.79%
Min EPS beat(4)-198.04%
Max EPS beat(4)50.98%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-200%
EPS NY rev (1m)0%
EPS NY rev (3m)-480%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-37.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 2.21
P/S 19.7
P/FCF N/A
P/OCF N/A
P/B 1.33
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)0.4
Fwd EY45.2%
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0.04
BVpS0.66
TBVpS-0.16
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -21.49%
ROE -40.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.09%
ROA(5y)N/A
ROE(3y)-34.59%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.83
Quick Ratio 0.32
Altman-Z -0.72
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y43%
EPS Next 2Y78.04%
EPS Next 3Y61.98%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y28.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-813.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-813.37%
OCF growth 3YN/A
OCF growth 5YN/A

CITIUS ONCOLOGY INC / CTOR Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CITIUS ONCOLOGY INC (CTOR) stock?

ChartMill assigns a fundamental rating of 1 / 10 to CTOR.


What is the valuation status of CITIUS ONCOLOGY INC (CTOR) stock?

ChartMill assigns a valuation rating of 4 / 10 to CITIUS ONCOLOGY INC (CTOR). This can be considered as Fairly Valued.


Can you provide the profitability details for CITIUS ONCOLOGY INC?

CITIUS ONCOLOGY INC (CTOR) has a profitability rating of 1 / 10.


How financially healthy is CITIUS ONCOLOGY INC?

The financial health rating of CITIUS ONCOLOGY INC (CTOR) is 1 / 10.